July 22 (Reuters) – GSK said on Wednesday the U.S. FDA has approved its drug for adults with a form of lung cancer who have previously received a targeted therapy.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Jonathan Ananda)
